Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others, said GeneGo.
GeneGo is also in the process of building disease-specific platforms in cancer and the cardiovascular area that include blueprint pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.
Julie Bryant, vice president of business development at GeneGo, said: “Bayer Schering Pharma was one of our first customers and we appreciate their loyalty. MetaCore is widely used in Bayer in multiple departments including bioinformatics, oncology, cardiology and women’s health for data mining and analysis of multiple omics experimental data such as gene expression and proteomics.”